UK firm GSK to pay $2.2bn over Zantac cancer claims

UK firm GSK to pay $2.2bn over Zantac cancer claims

GSK agrees to pay $2.2bn to settle US Zantac cancer cases. The settlements cover 93% of claims, including a whistleblower complaint. GSK denies wrongdoing, removing financial risks from ongoing litigation.

Read More

Did you find this insightful?